COMPOUND PROFILE / COMBINATIONS
Ipamorelin + CJC-1295 No DAC.
Research draftThis entry combines ipamorelin with CJC-1295 No DAC or modified GRF 1-29.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Identity and evidence review notes
No matched primary reference supports a therapeutic claim in this content pass. Retain the evidence gap; do not substitute seller claims.
Component references are background only. No directly matched controlled combination result was established in this pass.
Overview
This entry combines ipamorelin with CJC-1295 No DAC or modified GRF 1-29.
Mechanism
It pairs ghrelin-receptor activity with shorter-acting GHRH signalling, subject to identity confirmation.
Human research
Community use is not a controlled clinical demonstration of the exact combination's benefit.
Preclinical & other research
Component experiments cannot validate every marketed mixture.
Safety & unknowns
Hormonal effects, glucose responses and long-term combined exposure are insufficiently assessed.
Regulatory status
No exact-combination authorisation was established; long-acting CJC trials cannot be inherited.
Reported use & evidence
The supplied Ipamorelin + CJC-1295 No DAC profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.